HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism

Hemodialysis International

Volumn 21, Issue , 2017, Pages S110-S124

  Haase, Volker H ^a,b,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anemia; erythropoietin; hypoxia inducible factor; iron; prolyl hydroxylase

Indexed keywords

ANTIANEMIC AGENT; DAPRODUSTAT; DS 1093; FERRITIN; FERROPORTIN; HEMOGLOBIN; HEPCIDIN; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; JNJ 42905343; JTZ 951; MOLIDUSTAT; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ROXADUSTAT; TRANSFERRIN; UNCLASSIFIED DRUG; VADADUSTAT; VASCULOTROPIN; ZYAN1; BARBITURIC ACID DERIVATIVE; EPO PROTEIN, HUMAN; ERYTHROPOIETIN; FG-4592; GLYCINE; IRON; ISOQUINOLINE DERIVATIVE; PICOLINIC ACID DERIVATIVE; PROLYL HYDROXYLASE INHIBITOR;

ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; ACUTE RESPIRATORY FAILURE; ANEMIA; CHRONIC KIDNEY FAILURE; CONSTIPATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ERYTHROPOIESIS; GASTROINTESTINAL HEMORRHAGE; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; HEMODIALYSIS; HUMAN; HYPOGLYCEMIA; IRON BINDING CAPACITY; IRON METABOLISM; NAUSEA; NONHUMAN; OXYGEN SENSING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; UREMIA; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

ANEMIA; BARBITURATES; CLINICAL TRIALS AS TOPIC; ERYTHROPOIESIS; ERYTHROPOIETIN; GLYCINE; HUMANS; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; IRON; ISOQUINOLINES; PICOLINIC ACIDS; PROLYL-HYDROXYLASE INHIBITORS; RENAL DIALYSIS;

EID: 85018716024     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/hdi.12567     Document Type: Review

References (128)

1. Jourdanet D. Influence de la Pression de L'air sur la vie de L'homme. Paris: G Masson; 1875.
2. Bert P. La Pression Barométrique. Recherches de Physiologie Expérimentale. Paris: G Masson; 1878.
3. Bert P. Sur la richesse en hemoglobine du sang des animaux vivant sur les hauts lieux. C R Acad Sci Paris. 1882; 94:805–807.
4. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem. 1977; 252:5558–5564.
5. Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature. 1985; 313:806–810.
6. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA. 1985; 82:7580–7584.
7. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992; 12:5447–5454.
8. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995; 270:1230–1237.
9. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995; 92:5510–5514.
10. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996; 16:4604–4613.
11. Maxwell PH, Pugh CW, Ratcliffe PJ. Inducible operation of the erythropoietin 3' enhancer in multiple cell lines: Evidence for a widespread oxygen-sensing mechanism. Proc Natl Acad Sci USA. 1993; 90:2423–2427.
12. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001; 292:468–472.
13. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science. 2001; 292:464–468.
14. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001; 107:43–54.
15. Kewley RJ, Whitelaw ML, Chapman-Smith A. The mammalian basic helix-loop-helix/PAS family of transcriptional regulators. Int J Biochem Cell Biol. 2004; 36:189–204.
16. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol. 1999; 15:551–578.
17. Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE. 2005; 2005:re12.
18. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol. 2001; 13:167–171.
19. Schodel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ, Mole DR. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood. 2011; 117:e207–e217.
20. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol. 2003; 23:9361–9374.
21. Morita M, Ohneda O, Yamashita T, et al. HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. Embo J. 2003; 22:1134–1146.
22. Scortegagna M, Ding K, Zhang Q, et al. HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood. 2005; 105:3133–3140.
23. Gruber M, Hu CJ, Johnson RS, Brown EJ, Keith B, Simon MC. Acute postnatal ablation of Hif-2alpha results in anemia. Proc Natl Acad Sci USA. 2007; 104:2301–2306.
24. Rankin EB, Biju MP, Liu Q, et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest. 2007; 117:1068–1077.
25. Kapitsinou PP, Liu Q, Unger TL, et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood. 2010; 116:3039–3048.
26. Mastrogiannaki M, Matak P, Keith B, Simon MC, Vaulont S, Peyssonnaux C. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest. 2009; 119:1159–1166.
27. Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010; 21:2151–2156.
28. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis [see comments]. Nature. 1999; 399:271–275.
29. Maynard MA, Qi H, Chung J, et al. Multiple splice variants of the human HIF-3alpha locus are targets of the VHL E3 ubiquitin ligase complex. J Biol Chem. 2003; 278:1032–1040.
30. Kaelin WG. Von Hippel-Lindau disease. Annu Rev Pathol. 2007; 2:145–173.
31. Lee FS, Percy MJ. The HIF pathway and erythrocytosis. Annu Rev Pathol. 2011; 6:165–192.
32. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. Mol Cell. 2008; 30:393–402.
33. Loenarz C, Schofield CJ. Expanding chemical biology of 2-oxoglutarate oxygenases. Nat Chem Biol. 2008; 4:152–156.
34. Pollard PJ, Briere JJ, Alam NA, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet. 2005; 14:2231–2239.
35. Isaacs JS, Jung YJ, Mole DR, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. Cancer Cell. 2005; 8:143–153.
36. Koury MJ, Haase VH. Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol. 2015; 11:394–410.
37. Obara N, Suzuki N, Kim K, Nagasawa T, Imagawa S, Yamamoto M. Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood. 2008; 111:5223–5232.
38. Kobayashi H, Liu Q, Binns TC, et al. Distinct subpopulations of FOXD1 stroma-derived cells regulate renal erythropoietin. J Clin Invest. 2016; 126:1926–1938.
39. Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev. 2013; 27:41–53.
40. Urrutia AA, Afzal A, Nelson J, Davidoff O, Gross KW, Haase VH. Prolyl-4-hydroxylase 2 and 3 coregulate murine erythropoietin in brain pericytes. Blood. 2016; 128:2550–2560.
41. Rankin EB, Rha J, Selak MA, et al. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol Cell Biol. 2009; 29:4527–4538.
42. Minamishima YA, Kaelin WG Jr. Reactivation of hepatic EPO synthesis in mice after PHD loss. Science. 2010; 329:407.
43. Lonnberg M, Garle M, Lonnberg L, Birgegard G. Patients with anaemia can shift from kidney to liver production of erythropoietin as shown by glycoform analysis. J Pharm Biomed Anal. 2013; 81–82:187–192.
44. Shah YM, Matsubara T, Ito S, Yim SH, Gonzalez FJ. Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metab. 2009; 9:152–164.
45. Mastrogiannaki M, Matak P, Delga S, Deschemin JC, Vaulont S, Peyssonnaux C. Deletion of HIF-2alpha in the enterocytes decreases the severity of tissue iron loading in hepcidin knockout mice. Blood. 2011; 119:587–590.
46. Rolfs A, Kvietikova I, Gassmann M, Wenger RH. Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. J Biol Chem. 1997; 272:20055–20062.
47. Lok CN, Ponka P. Identification of a hypoxia response element in the transferrin receptor gene. J Biol Chem. 1999; 274:24147–24152.
48. Tacchini L, Bianchi L, Bernelli-Zazzera A, Cairo G. Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J Biol Chem. 1999; 274:24142–24146.
49. Mukhopadhyay CK, Mazumder B, Fox PL. Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem. 2000; 275:21048–21054.
50. Lee PJ, Jiang BH, Chin BY, et al. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem. 1997; 272:5375–5381.
51. Taylor M, Qu A, Anderson ER, et al. Hypoxia-inducible factor-2alpha mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice. Gastroenterology. 2011; 140:2044–2055.
52. Ganz T. Molecular control of iron transport. J Am Soc Nephrol. 2007; 18:394–400.
53. Zaritsky J, Young B, Wang HJ, et al. Hepcidin–a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4:1051–1056.
54. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002; 110:1037–1044.
55. Gordeuk VR, Miasnikova GY, Sergueeva AI, et al. Chuvash polycythemia VHLR200W mutation is associated with down-regulation of hepcidin expression. Blood. 2011; 118:5278–5282.
56. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest. 2007; 117:1926–1932.
57. Mastrogiannaki M, Matak P, Mathieu JR, et al. Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis. Haematologica. 2012; 97:827–834.
58. Liu Q, Davidoff O, Niss K, Haase VH. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest. 2012; 122:4635–4644.
59. Sanchez M, Galy B, Muckenthaler MU, Hentze MW. Iron-regulatory proteins limit hypoxia-inducible factor-2alpha expression in iron deficiency. Nat Struct Mol Biol. 2007; 14:420–426.
60. Ghosh MC, Zhang DL, Jeong SY, et al. Deletion of iron regulatory protein 1 causes polycythemia and pulmonary hypertension in mice through translational derepression of HIF2alpha. Cell Metab. 2013; 17:271–281.
61. Anderson SA, Nizzi CP, Chang YI, et al. The IRP1-HIF-2alpha axis coordinates iron and oxygen sensing with erythropoiesis and iron absorption. Cell Metab. 2013; 17:282–290.
62. Wilkinson N, Pantopoulos K. IRP1 regulates erythropoiesis and systemic iron homeostasis by controlling HIF2alpha mRNA translation. Blood. 2013; 122:1658–1668.
63. Chin K, Yu X, Beleslin-Cokic B, et al. Production and processing of erythropoietin receptor transcripts in brain. Brain Res Mol Brain Res. 2000; 81:29–42.
64. Manalo DJ, Rowan A, Lavoie T, et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood. 2005; 105:659–669.
65. Yoon D, Pastore YD, Divoky V, et al. HIF-1alpha -deficiency results in dysregulated EPO signaling and iron homeostasis in mouse development. J Biol Chem. 2006; 281:25703–25711.
66. Liu YL, Ang SO, Weigent DA, Prchal JT, Bloomer JR. Regulation of ferrochelatase gene expression by hypoxia. Life Sci. 2004; 75:2035–2043.
67. Hofer T, Wenger RH, Kramer MF, Ferreira GC, Gassmann M. Hypoxic up-regulation of erythroid 5-aminolevulinate synthase. Blood. 2003; 101:348–350.
68. Adelman DM, Maltepe E, Simon MC. Multilineage embryonic hematopoiesis requires hypoxic ARNT activity. Genes Dev. 1999; 13:2478–2483.
69. Yamashita T, Ohneda O, Sakiyama A, Iwata F, Ohneda K, Fujii-Kuriyama Y. The microenvironment for erythropoiesis is regulated by HIF-2alpha through VCAM-1 in endothelial cells. Blood. 2008; 112:1482–1492.
70. Fishbane S, Nissenson AR. Anemia management in chronic kidney disease. Kidney Int. 2010; 117:S3–S9.
71. Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur J Haematol. 2007; 78:183–205.
72. Jelkmann W. The ESA scenario gets complex: from biosimilar epoetins to activin traps. Nephrol Dial Transplant. 2015; 30:553–559.
73. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339:584–590.
74. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355:2085–2098.
75. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361:2019–2032.
76. Vaziri ND, Zhou XJ. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant. 2009; 24:1082–1088.
77. McCullough PA, Barnhart HX, Inrig JK, et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol. 2013; 37:549–558.
78. Besarab A, Frinak S, Yee J. What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway? Adv Chronic Kidney Dis. 2009; 16:131–142.
79. Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010; 363:1146–1155.
80. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008; 74:791–798.
81. Holdstock L, Meadowcroft AM, Maier R, et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol. 2016; 27:1234–1244.
82. Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: A phase 2, randomized, 6- to 19-week, open-Label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis. 2016; 67:912–924.
83. Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015; 30:1665–1673.
84. Provenzano R, Besarab A, Sun CH, et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clin J Am Soc Nephrol. 2016; 11:982–991.
85. Besarab A, Chernyavskaya E, Motylev I, et al. Roxadustat (FG-4592): Correction of anemia in incident dialysis patients. J Am Soc Nephrol. 2016; 27:1225–1233.
86. Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016; 90:1115–1122.
87. Souma T, Nezu M, Nakano D, et al. Erythropoietin synthesis in renal myofibroblasts is restored by activation of hypoxia signaling. J Am Soc Nephrol. 2016; 27:428–438.
88. Haase VH, Hartman CS, Maroni B, Farzaneh-Far R, McCullough PA. Vadadustat—A novel, oral treatment for anemia of CKD—Maintains stable hemoglobin levels in dialysis patients converting from Erythropoiesis-Stimulating Agent (ESA). National Kidney Foundation Spring Clinical Meeting. Boston, MA, 2016; Abstract 171.
89. Haase VH, Khawaja Z, Chan J, et al. Vadadustat maintains Hemoglobin (Hb) levels in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) patients independent of systemic inflammation or prior dose of Erythropoiesis-Stimulating Agent (ESA). J Am Soc Nephrol. 2016; 27:318A.
90. Brigandi RA, Johnson B, Oei C, et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: A 28-day, phase 2A randomized trial. Am J Kidney Dis. 2016; 67:861–871.
91. Hara K, Takahashi N, Wakamatsu A, Caltabiano S. Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. Drug Metab Pharmacokinet. 2015; 30:410–418.
92. Akizawa T, Tsubakihara Y, Nangaku M, et al. Effects of Daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. Am J Nephrol. 2017; 45:127–135.
93. Flamme I, Oehme F, Ellinghaus P, Jeske M, Keldenich J, Thuss U. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One. 2014; 9:e111838
94. MacDougall IC, Akizawa T, Berns J, Lentini S, Bernhardt T. Molidustat increases hemoglobin in erythropoiesis stimulating agents (ESA)—Naive patients with chronic kidney diseases not on dialysis (CKD-ND). Nephrol Dial Transplant. 2016; 31(Suppl 1):i16.
95. MacDougall IC, Akizawa T, Berns J, Bernhardt T, Krüger T. Safety and efficacy of molidustat in erythropoiesis stimulating agenst (ESA) pre-treated anemic patients with chronic kidney disease not on dialysis (CKD-ND). Nephrol Dial Transplant. 2016; 31(Suppl 1):i193.
96. Akizawa T, Hanaki K, Arai M. JTZ-591, an oral novel HIF-PHD inhibitor, elevates hemoglobin in Japanese anemic patients with chronic kidney disease not on dialysis. Nephrol Dial Transplant. 2015; 30(Suppl 3):iii8–iii10.
97. Patel H, Joharapurkar AA, Pandya VB, et al. Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia. Xenobiotica. 2017; 19:1–8. [Epub ahead of print]
98. Jain MR, Joharapurkar AA, Pandya V, et al. Pharmacological characterization of ZYAN1, a novel prolyl hydroxylase inhibitor for the treatment of anemia. Drug Res (Stuttg). 2016; 66:107–112.
99. Barrett TD, Palomino HL, Brondstetter TI, et al. Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats. Br J Pharmacol. 2015; 172:4078–4088.
100. Hartman C, Smith MT, Flinn C, et al. AKB-6548, a new hypoxia-inducible factor prolyl hydroxylase inhibitor increases hemoglobin while decreasing ferritin in a 28-day, phase 2a dose escalation study in stage 3 and 4 chronic kidney disease patients with anemia. J Am Soc Nephrol. 2011; 22:435A.
101. Brigandi RA, Ariazi JL, Duffy KJ, Luo L, Adams DF, Erickson-Miller CL. The prolyl hydroxylase inhibitor, GSK1278863A, induced EPO in vitro and efficient erythropoiesis leading to increased hemoglobin in vivo. J Am Soc Nephrol. 2010; 21:722A.
102. Astellas Pharma Inc. News release: the FDA accepts the complete response for clinical holds of FG-2216*/FG-4592 for the treatment of anemia. astellas.com [online], http://www.astellas.com/en/corporate/news/pdf/080402_eg.pdf (2008).
103. Shalwitz R, Hartman C, Flinn C, Shalwitz I, Logan DK. AKB-6548, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor reduces hepcidin and ferritin while it increases reticulocyte production and total iron binding capacity in healthy adults. J Am Soc Nephrol. 2011; 22:45A.
104. Shalwitz R, Hartman C, Flinn C, et al. AKB-6548: A new hypoxia-inducible factor prolyl hydroxylase inhibitor, increases hemoglobin in chronic kidney disease patients without increasing basal erythropoietin levels. J Am Soc Nephrol. 2012; 23:56A.
105. Seeley TW, Sternlicht MD, Klaus SJ, Neff TB, Liu DY. Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer. Hypoxia. 2017; 5:1–9.
106. Gordeuk VR, Sergueeva AI, Miasnikova GY, et al. Congenital disorder of oxygen sensing: Association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood. 2004; 103:3924–3932.
107. Gordeuk VR, Prchal JT. Vascular complications in Chuvash polycythemia. Semin Thromb Hemost. 2006; 32:289–294.
108. Formenti F, Beer PA, Croft QP, et al. Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: Von Hippel-Lindau disease and HIF-2{alpha} gain-of-function mutation. FASEB J. 2011; 25:2001–2011.
109. Semenza GL. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol. 2014; 9:47–71.
110. Hickey MM, Richardson T, Wang T, et al. The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. J Clin Invest. 2010; 120:827–839.
111. Kapitsinou PP, Rajendran G, Astleford L, et al. The endothelial prolyl-4-hydroxylase domain 2/hypoxia-inducible factor 2 axis regulates pulmonary artery pressure in mice. Mol Cell Biol. 2016; 36:1584–1594.
112. Cowburn AS, Crosby A, Macias D, et al. HIF2alpha-arginase axis is essential for the development of pulmonary hypertension. Proc Natl Acad Sci USA. 2016; 113:8801–8806.
113. Bryant AJ, Carrick RP, McConaha ME, et al. Endothelial HIF signaling regulates pulmonary fibrosis-associated pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2016; 310:L249–L262.
114. Dai Z, Li M, Wharton J, Zhu MM, Zhao YY. Prolyl-4 hydroxylase 2 (PHD2) deficiency in endothelial cells and hematopoietic cells induces obliterative vascular remodeling and severe pulmonary arterial hypertension in mice and humans through hypoxia-inducible factor-2alpha. Circulation. 2016; 133:2447–2458.
115. Bolignano D, Rastelli S, Agarwal R, et al. Pulmonary hypertension in CKD. Am J Kidney Dis. 2013; 61:612–622.
116. Brigandi RA, Russ SF, Al-Banna M, Zhang J, Erickson-Miller CL, Peng B. Prolylhydroxylase inhibitor modulation of erythropoietin in a randomized placebo controlled trial. J Am Soc Nephrol. 2010; 21:390A.
117. Haase VH. Renal cancer: oxygen meets metabolism. Exp Cell Res. 2012; 318:1057–1067.
118. Girgis CM, Cheng K, Scott CH, Gunton JE. Novel links between HIFs, type 2 diabetes, and metabolic syndrome. Trends Endocrinol Metab. 2012; 23:372–380.
119. Gunton JE, Kulkarni RN, Yim S, et al. Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell. 2005; 122:337–349.
120. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: Sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2012; 12:9–22.
121. Haase VH. Mechanisms of hypoxia responses in renal tissue. J Am Soc Nephrol. 2013; 24:537–541.
122. Nangaku M, Rosenberger C, Heyman SN, Eckardt KU. Regulation of hypoxia-inducible factor in kidney disease. Clin Exp Pharmacol Physiol. 2013; 40:148–157.
123. Mokas S, Lariviere R, Lamalice L, et al. Hypoxia-inducible factor-1 plays a role in phosphate-induced vascular smooth muscle cell calcification. Kidney Int. 2016; 90:598–609.
124. Francis C, David V. Inflammation regulates fibroblast growth factor 23 production. Curr Opin Nephrol Hypertens. 2016; 25:325–332.
125. Zhang Q, Doucet M, Tomlinson RE, et al. The hypoxia-inducible factor-1alpha activates ectopic production of fibroblast growth factor 23 in tumor-induced osteomalacia. Bone Res. 2016; 4:16011
126. Mahon PC, Hirota K, Semenza GL. FIH-1: A novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001; 15:2675–2686.
127. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002; 16:1466–1471.
128. McNeill LA, Hewitson KS, Claridge TD, Seibel JF, Horsfall LE, Schofield CJ. Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803. Biochem J. 2002; 367:571–575.